Analysis of antiemetic effect of various dosage regimens of azasetron hydrochloride based on 5-HT3 receptor occupancy of serotonin

Yakugaku Zasshi

Volumn 127, Issue 2, 2007, Pages 353-357

  Yamada, Yasuhiko ^a   Fujita, Mina ^b   Okuyama, Kiyoshi ^a   Takayanagi, Risa ^a   Ozeki, Takeshi ^a   Yokoyama, Haruko ^a   Iga, Tatsuji ^c  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

5 HT3 receptor occupancy; Antiemetic effect; Azasetron hydrochloride; Cisplatin; Dosage regimen; Serotonin

Indexed keywords

ANTINEOPLASTIC AGENT; AZASETRON; CISPLATIN; SEROTONIN; SEROTONIN RECEPTOR;

ANTIEMETIC ACTIVITY; ARTICLE; CHEMOTHERAPY; COMPETITIVE INHIBITION; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG RECEPTOR BINDING; GASTROINTESTINAL TRACT; HUMAN; NAUSEA AND VOMITING; RECEPTOR OCCUPANCY; SEROTONIN RELEASE;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; BINDING, COMPETITIVE; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; HUMANS; INJECTIONS, INTRAVENOUS; MODELS, BIOLOGICAL; NAUSEA; OXAZINES; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN; SEROTONIN ANTAGONISTS; TIME FACTORS; VOMITING;

EID: 33846838755     PISSN: 00316903     EISSN: 13475231     Source Type: Journal    
DOI: 10.1248/yakushi.127.353     Document Type: Article

References (20)

1. Urushizaki I., Jpn. J. Cancer Chemother., 17, 1959-1969 (1990).
2. Merrifield K. R., Chaffee B. J., Clin. Pharm., 8, 187 (1989).
3. Laszo J., Drugs, 25 Suppl 1, 1 (1983).
4. Coates A., Abraham S., Kaye S. B., Sowerbutts T., Frewin C., Fox R. M., Tattersall M. H., Eur. J. Cancer Clin. Oncol., 19, 203-208 (1983).
5. Joss R. A., Brand B. C., Buser K. S., Cerny T., Eur. J. Cancer, 26 Suppl 1, S2-8 (1990).
6. Sridhar K. S., Donnelly E., Cancer, 61, 1508. 1517 (1988).
7. Andrews P. L. R., Rapeport W. G., Sanger G. J., TIPS, 8, 334-341 (1988).
8. Mitchelson F., Drugs, 43, 295-315 (1992).
9. Cubeddu L. X., Hoffmann I. S., Fuenmayor N. T., Finn A. L., N. Engl. J. Med., 322, 810. 816 (1990).
10. Tortorice P. V., O'Connell M. B., Pharmacotherapy, 10, 129-145 (1990).
11. Kimura E., Niimi S., Watanabe A., Tanaka T., Jpn. J. Cancer Chemother., 24, 855-859 (1997).
12. Kimura E., Niimi S., Watanabe A., Akiyama M., Tanaka T., Jpn. J. Cancer Chemother., 23, 477-481 (1996).
13. Yamada Y., Sugiura M., Higo K., Ozeki T., Takayanagi R., Okuyama K., Yamamoto K., Satoh H., Sawada Y., Iga T., Cancer Chemother. Pharmacol., 54, 185-190 (2004).
14. Igarashi S., Tanaka K., Yamamura H., Sawai K., Isobe M., Masui H., Kataoka H., Isikawa M., Oka T., Clin. Rep., 26, 2535-2547 (1992).
15. Sakamori M., Takehara S., Setoguchi M., Folia Pharmacol. Jpn., 100, 137-142 (1992).
16. Cubeddu L. X., Hoffmann I. S., Fuenmayor N. T., Malave J. J., Br. J. Cancer, 66, 198-203 (1992).
17. Cubeddu L. X., Oncology, 53 Suppl 1, 18-25 (1996).
18. Robert H., Resnick M. D., Seymour J. G., Gastroenterology, 41, 119-121 (1961).
19. Yamada Y., Sawada Y., Takayanagi R., Ito K., Nakamura K., Iga T., Xenobiol. Metab. Dispos., 8, 247-261 (1993).
20. Yamada Y., Sawada Y., Ito K., Nakamura K., Iga T., Biol. Pharm. Bull., 16, 1251-1259 (1993).